| Literature DB >> 24724089 |
Grete Flemmen1, Runar Unhjem2, Eivind Wang2.
Abstract
Patients with substance use disorder (SUD) suffer a higher risk of cardiovascular disease and other lifestyle diseases compared to the general population. High intensity training has been shown to effectively reduce this risk, and therefore we aimed to examine the feasibility and effect of such training in SUD patients in clinical treatment in the present study. 17 males and 7 females (32 ± 8 yr) in treatment were randomized to either a training group (TG), treadmill interval training in 4 × 4 minutes at 90-95% of maximal heart rate, 3 days a week for 8 weeks, or a conventional rehabilitation control group (CG). Baseline values for both groups combined at inclusion were 44 ± 8 (males) and 34 ± 9 (females) mL · min(-1) · kg(-1), respectively. 9/12 and 7/12 patients completed the TG and CG, respectively. Only the TG significantly improved (15 ± 7%) their maximal oxygen consumption (VO2max), from 42.3 ± 7.2 mL · min(-1) · kg(-1) at pretest to 48.7 ± 9.2 mL · min(-1) · kg(-1) at posttest. No between-group differences were observed in work economy, and level of insomnia (ISI) or anxiety and depression (HAD), but a significant within-group improvement in depression was apparent for the TG. High intensity training was feasible for SUD patients in treatment. This training form should be implemented as a part of the rehabilitation since it, in contrast to the conventional treatment, represents a risk reduction for cardiovascular disease and premature death.Entities:
Mesh:
Year: 2014 PMID: 24724089 PMCID: PMC3958650 DOI: 10.1155/2014/616935
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Recruitment, randomization, and withdrawal of SUD patients throughout the study.
Patient characteristics and medical use.
| TG | CG | Combined | |
|---|---|---|---|
| Men/women ( | 8/1 | 5/2 | 13/3 |
| Age (yr) | 33 ± 11 | 31 ± 8 | 32 ± 9 |
| Height (cm) | 177 ± 10 | 175 ± 10 | 176 ± 10 |
| Weight (kg) | 84.1 ± 14.9 | 87.9 ± 20.8 | 85.8 ± 17.2 |
| Current smoker | 8 | 6 | 14 |
| Drug use debut (age) | 15 ± 6 | 17 ± 4 | 16 ± 5 |
| Duration of abuse (yr) | 17 ± 8 | 12 ± 4 | 15 ± 7 |
| Primary drug | |||
| Heroin | 1 | 1 | 2 |
| BZD, Sed, Hypn | 1 | 1 | 2 |
| Amphetamine | 4 | 4 | 8 |
| Cannabis | 3 | 1 | 4 |
| Secondary drug | |||
| Alcohol | 2 | 0 | 2 |
| Heroin | 1 | 1 | 2 |
| Opiates, painkillers | 2 | 1 | 3 |
| Amphetamine | 1 | 0 | 1 |
| Cannabis | 3 | 5 | 8 |
| Symptoms for medicine prescription: | |||
| ADHD | 0 | 1 | 1 |
| Allergies | 1 | 2 | 3 |
| Anxiety | 2 | 1 | 3 |
| Arthritis | 0 | 1 | 1 |
| Asthma/COPD | 0 | 1 | 1 |
| Depression | 1 | 2 | 3 |
| Epilepsy | 0 | 1 | 1 |
| Hypertension | 3 | 1 | 4 |
| Schizophrenia/bipolar | 1 | 2 | 3 |
| Substitutional treatment | 1 | 1 | 2 |
| Other | 0 | 3 | 3 |
Data are presented as mean ± SD; TG: training group; CG: control group, Type of medication is reported on indication of symptoms according to common directory. The prescribed medicines in substitutional treatment are methadone and suboxone. Others: skin disorder, pain, and inflammation.
Changes in physiological parameters from pre- to posttest.
| TG ( | CG ( | |||
|---|---|---|---|---|
| Pre | Post | Pre | Post | |
| VO2max | ||||
| (L·min−1) | 3.60 ± 0.91 | 4.15 ± 1.03∗∗# | 3.43 ± 0.66 | 3.54 ± 0.65 |
| (mL·kg−1·min−1) | 42.3 ± 7.2 | 48.7 ± 9.2∗∗# | 41.8 ± 12.3 | 42.6 ± 12.1 |
|
| 109.2 ± 28.6 | 125.9 ± 36.8∗∗# | 103.5 ± 24.4 | 103.2 ± 23.9 |
| RER | 1.09 ± 0.03 | 1.10 ± 0.02 | 1.17 ± 0.11 | 1.14 ± 0.06 |
| HRmax (beats·min−1) | 180 ± 11 | 181 ± 14 | 189 ± 7 | 188 ± 7 |
| [La−]b | 9.12 ± 2.41 | 10.65 ± 1.69 | 8.04 ± 3.54 | 9.21 ± 2.01 |
Data are presented as mean ± SD. TG: training group; CG: control group; VO2max: maximal oxygen uptake; V : ventilation; RER: respiratory exchange ratio; HRmax: maximal heart rate; [La−]b: lactate concentration in blood, **P < 0.01, difference within group from pre- to posttest, # P < 0.05, differences in changes from pre- to posttest between groups.
Figure 2Maximal oxygen consumption before and after the training intervention. Data are presented as mean ± SE. *P < 0.01, difference within group from pre- to posttest, # P < 0.05, differences in changes from pre- to posttest between groups.
Work economy measured at 4.5 km·h−1 and 5% inclination at pre- and posttest.
| TG ( | CG ( | |||
|---|---|---|---|---|
| Pre | Post | Pre | Post | |
| VO2 | ||||
| (L·min−1) | 1.54 ± 0.24 | 1.61 ± 0.28 | 1.70 ± 0.36 | 1.77 ± 0.43 |
| (ML·kg−1·min−1) | 18.5 ± 1.1 | 18.9 ± 1.3 | 19.6 ± 2.3 | 20.2 ± 1.4 |
|
| 35.1 ± 4.4 | 33.3 ± 5.3 | 38.3 ± 9.3 | 41.1 ± 9.0 |
| RER | 0.90 ± 0.04 | 0.89 ± 0.08 | 0.93 ± 0.05 | 0.94 ± 0.07 |
| HRmax (beats·min−1) | 116 ± 17 | 105 ± 18 | 116 ± 18 | 119 ± 9 |
Data are presented as mean ± SD. TG: training group; CG: control group; VO2: oxygen uptake; V : ventilation; RER: respiratory exchange ratio; HRmax: maximal heart rate.
Psychological changes from pre- to posttest (scores from the insomnia severity index and hospital anxiety and depression scale questionnaires).
| TG ( | CG ( | |||
|---|---|---|---|---|
| Pre | Post | Pre | Post | |
| Anxiety | 9.4 ± 3.5 | 8.6 ± 2.5 | 9.1 ± 5.3 | 6.3 ± 3.4* |
| Depression | 8.5 ± 4.8 | 5.3 ± 3.9* | 6.0 ± 3.5 | 4.6 ± 3.5 |
| Insomnia | 10.6 ± 5.4 | 8.9 ± 5.1 | 10.9 ± 10.1 | 9.1 ± 5.0 |
Data are presented as means ± SD. TG: training group; CG: control group. *P < 0.05, difference within group from pre- to posttest.